{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.7","upperLimit":"47.2","value":"27.6"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"36.4","value":"11.8"},{"groupId":"OG002","lowerLimit":"32.1","upperLimit":"54.1","value":"42.9"},{"groupId":"OG003","lowerLimit":"34.8","upperLimit":"63.4","value":"49.0"},{"groupId":"OG004","lowerLimit":"18.0","upperLimit":"51.8","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"84"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"33"}],"units":"Participants"}],"description":"Molecular response was assessed using BCR-ABL transcript levels measurement by real-time quantitative polymerase chain reaction (qPCR). (CMR) is defined as absence of BCR-ABL rearrangements by real-time qPCR analysis. The percentage of treated participants with CMR is reported by arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Children and adolescents with CP-CML who were resistant or intolerant to imatinib received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG000","title":"Cohort 1"},{"description":"Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.","id":"OG001","title":"Cohort 2"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD or powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG002","title":"Cohort 3"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib tablets at 60 mg/m2 QD on a continuous oral regimen.","id":"OG003","title":"Cohort 3a"},{"description":"Children and adolescents with CP-CML who were treatment-naive received dasatinib powder for oral suspension (PFOS) at 72 mg/m2 QD on a continuous oral regimen.","id":"OG004","title":"Cohort 3b"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From date of first treatment to date of CMR (assessed up to Jan 2025, approximately 15 years and 10 months)","title":"Complete Molecular Response (CMR) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}